Rani Therapeutics Holdings (RANI) Earnings Analysis
Rani Therapeutics Holdings (RANI) next reports earnings on 2026-08-06, consensus EPS -0.05 USD. Last quarter (2026-05-15) it beat with EPS -0.04 USD vs -0.06 USD est (+33.3%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -2.19.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does RANI next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.05 USD |
| Revenue estimate | 0.00B |
RANI earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-15 | -0.04 USD | -0.06 USD | +33.3% | Beat |
| 2026-03-26 | -0.07 USD | -0.03 USD | -133.3% | Miss |
| 2025-11-06 | -0.12 USD | -0.09 USD | -33.3% | Miss |
| 2025-08-07 | -0.18 USD | -0.19 USD | +5.3% | Beat |
| 2025-03-31 | -0.27 USD | -0.24 USD | -12.5% | Miss |
| 2024-11-14 | -0.24 USD | -0.22 USD | -9.1% | Miss |
Beat rate: 2/6 (33%) over reported quarters with consensus data.
RANI valuation and analyst view
| Trailing P/E | -2.19 |
|---|---|
| Trailing EPS | -0.16357 USD |
| Price / book | 5.68 |
| Dividend yield | 0.00% |
| Market cap | 0.06B |
| Analyst consensus | Buy (7 buy / 0 hold / 0 sell) |
Related research pages
Frequently asked questions
When is Rani Therapeutics Holdings (RANI)'s next earnings date?
Rani Therapeutics Holdings is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.05 USD and revenue estimate of 0.00B.
Did RANI beat earnings last quarter?
In its 2026-05-15 report, RANI posted EPS of -0.04 USD versus a -0.06 USD estimate — a beat of 33.3%.
What is RANI's earnings track record?
Over the last 6 reported quarters with consensus data, RANI beat estimates 2 times (33%).
What is RANI's current P/E ratio and EPS?
RANI trades at a trailing P/E of -2.19 on trailing EPS of -0.16357030156225694 USD.
What do analysts rate RANI?
Analyst consensus is "Buy" across 7 ratings (0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell).